EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study

Eslam Montaser iD, Kanchan Bhasin iD, Davida Kruger, Halis Kaan Akturk iD, Andrew Ahmann iD, Janet K Snell-Bergeon iD, Viral N Shah iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71287 ↗

At a glance

Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2026. Written by Eslam Montaser and 6 co-authors. Institution: Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin. 15 references. The full text is freely available (open access, CC BY 4.0). Funded by: Novo Nordisk, Breakthrough T1D.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Aims

To evaluate changes in glycaemic control following semaglutide discontinuation in adults with Type 1 diabetes and obesity who completed the ADJUST‐T1D randomised controlled trial. Materials and Methods Continuous glucose monitoring (CGM) data were collected during a 12‐week extension phase after the ADJUST‐T1D trial. Analyses included participants previously randomised to semaglutide who discontinued treatment ( n = 16) and participants previously randomised to placebo who did not receive a glucagon‐like peptide‐1 receptor agonist during follow‐up ( n = 22). Changes in CGM‐derived metrics from Week 26 to the extension phase were compared using Wilcoxon rank‐sum tests with Benjamini–Hochberg adjustment. Analysis of covariance (ANCOVA) adjusting for Week 26 values was performed as a sensitivity analysis.

Results

Compared with placebo, participants who discontinued semaglutide experienced a greater decline in time in range (70–180 mg/dL) (median change −3.6% vs. 1.5%; adjusted p = 0.044). Semaglutide discontinuation was also associated with greater increases in glucose standard deviation (6.0 vs. 1.2 mg/dL; adjusted p = 0.044) and coefficient of variation (3.1% vs. 1.1%; adjusted p = 0.044), indicating worsening glycaemic variability. Time above range (> 180 mg/dL) increased numerically but did not remain significant after adjustment (adjusted p = 0.064). No significant between‐group differences were observed in hypoglycaemia‐related CGM metrics. ANCOVA analyses showed consistent findings.

Conclusions

In adults with Type 1 diabetes and obesity, semaglutide discontinuation was associated with a greater decline in time in range and increased glycaemic variability compared with placebo over 12 weeks. These findings suggest that glycaemic benefits achieved during treatment may not be fully sustained following withdrawal.

Subjects

MeSH terms (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulinSemaglutideAdultFemaleHumansMaleMiddle AgedContinuous Glucose MonitoringGlycated HemoglobinGlycemic ControlHypoglycemiaInsulin Infusion SystemsObesityTreatment InterruptionGlucagon-Like Peptide-1 Receptor Agonists

Author keywords

GLP‐1 receptor agonistType 1 diabetesautomated insulin deliverycontinuous glucose monitoringglycaemic variability

Substances

Blood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinSemaglutideGlucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Division of Endocrinology and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Division of Endocrinology Diabetes and Metabolism, Henry Ford Hospital, Detroit, Michigan, USA.
  • Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
  • OHSU Harold Schnitzer Diabetes Health Center, Portland, Oregon, USA.
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID profiles: Eslam Montaser, Kanchan Bhasin, Halis Kaan Akturk, Andrew Ahmann, Janet K Snell-Bergeon, Viral N Shah

Funding

  • Novo Nordisk
  • Breakthrough T1D

Cite

APA

Montaser, E., Bhasin, K., Kruger, D., Akturk, H. K., Ahmann, A., Snell-Bergeon, J. K., & Shah, V. N. (2026). Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71287

Vancouver

Montaser E, Bhasin K, Kruger D, Akturk HK, Ahmann A, Snell-Bergeon JK, et al. Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71287

BibTeX
@article{Montaser2026,
  author = {Montaser, Eslam and Bhasin, Kanchan and Kruger, Davida and Akturk, Halis Kaan and Ahmann, Andrew and Snell-Bergeon, Janet K and Shah, Viral N},
  title = {Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Extension Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71287}
}
Start for free →